CIMETIDINE TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Osta kohe

Laadi alla Toote omadused (SPC)
10-02-2022

Toimeaine:

CIMETIDINE

Saadav alates:

AA PHARMA INC

ATC kood:

A02BA01

INN (Rahvusvaheline Nimetus):

CIMETIDINE

Annus:

800MG

Ravimvorm:

TABLET

Koostis:

CIMETIDINE 800MG

Manustamisviis:

ORAL

Ühikuid pakis:

100/500

Retsepti tüüp:

Prescription

Terapeutiline ala:

HISTAMINE H2-ANTAGONISTS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0111925006; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2019-01-22

Toote omadused

                                _CIMETIDINE (Cimetidine) _
_ _
_Page 1 of 28_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR CIMETIDINE
Cimetidine
Tablet, 200, 300, 400, 600 and 800 mg, oral
USP
ATC Code: A02BA01
Histamine H
2
- Antagonist
AA PHARMA INC
Vaughan, Ontario
L4K 4N7
www.aapharma.ca
Date of Initial Authorization:
DEC 31, 1982
Date of Revision:
FEB 10, 2022
Submission Control Number: 256184
_CIMETIDINE (Cimetidine) _
_Page 2 of 28_
RECENT MAJOR LABEL CHANGES
1 Indications, 1.2 Geriatrics
02/2022
4 Dosage and Administration, 4.2 Recommended Dose and
Dosage Adjustment
02/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
TABLE OF CONTENTS
................................................................................................................2
1
INDICATIONS
................................................................................................................4
1.1
Pediatrics
............................................................................................................4
1.2
Geriatrics.............................................................................................................4
2
CONTRAINDICATIONS
...................................................................................................4
4
DOSAGE AND
ADMINISTRATION...................................................................................4
4.1
Dosing considerations
..........................................................................................4
4.2
Recommended Dose and Dosage
Adjustment.......................................................5
4.5
Missed Dose
........................................................................................................6
5
OVERDOSAGE
...............................................................................................................6
6
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING
...................................7
7
WARNINGS AND PRECAUTIONS
......................................
                                
                                Lugege kogu dokumenti
                                
                            

Dokumendid teistes keeltes

Toote omadused Toote omadused prantsuse 10-02-2022

Otsige selle tootega seotud teateid

Vaadake dokumentide ajalugu